EGFR Inhibitors in Advanced NSCLC: Who, When, and Why?

Slides:



Advertisements
Similar presentations
James R. Rigas Comprehensive Thoracic Oncology Program
Advertisements

Using Non-targeted Therapies in Targeted Lung Cancer Populations Nathan Pennell, M.D., Ph.D. September 6, 2014.
A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Inhibitor Gefitinb in Completely Resected Stage.
Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.
Network Experience of TKI inhibitors as 1 st line use in advanced NSCLC Dr Jill Gardiner and Mr Steve Williamson April 2012.
First-Line TKI Use in EGFR Mutation-Positive NSCLC
Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.
Clinicopathologic Features of EML4-ALK Mutant Lung Cancer Shaw AT et al. ASCO 2009; Abstract (Poster)
Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.
POPLAR: Atezolizumab Improved Survival vs Docetaxel in Patients With Advanced NSCLC and Increasing Levels of PD-L1 Expression CCO Independent Conference.
J Thorac Oncol. 2012;7: 1653–1660) David P. Carbone, MD, PhD,* Keyue Ding, PhD,† Heinrich Roder, PhD,‡ Julia Grigorieva, PhD,‡ Joanna Roder, PhD,‡ Ming-Sound.
Volume 18, Issue 6, Pages (September 2015)
Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non- small-cell lung cancer (NSCLC) patients with good performance status.
Rosell R et al. Proc ASCO 2011;Abstract 7503.
advanced lung adenocarcinoma subtype
Patient Case 1 Patient Case 1: PET/CT Scan.
A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer
Strategies for the Management of EGFR TKI Resistance in Advanced NSCLC
Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.
The New Taxonomy of Metastatic NSCLC and Physician Treatment Based on Pathologic and Molecular Characteristics The New Taxonomy of Metastatic Non-Small.
What to Do Next: Sequencing of Therapy in Patients With Metastatic CRC
Fundamental Concepts in the Diagnosis of Advanced NSCLC
Assessing the Impact: New Data in T790+ NSCLC
New Patient Journeys in Non-small cell lung cancer
The Genomics of Cancer and Molecular Testing:
Updates in Lung Cancer: Insights From Vienna
Updates and Perspectives on Third-Generation EFGR TKIs in Advanced NSCLC.
Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?
Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.
Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.
T790M Mutation-Positive NSCLC: A Multidisciplinary Case Conference
Locally Advanced NSCLC Implementing Innovation
Treating mRCC After Initial Antiangiogenic Therapy:
Maintenance paradigm in non-squamous NSCLC
Moving Care Forward in Advanced NSCLC
Serum vs FNA:.
Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.
Treatment of Stage IV Non-small Cell Lung Cancer
Beyond Erlotinib: Better EGFR Inhibitors?
Locally Advanced Lung Cancer
Putting Evidence Into Practice: Highlights From Toronto
Progress of the NSCLC Revolution
Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.
Patient-Centered Management in Advanced Non-Small Cell Lung Cancer
Practical Strategies to Guideline-Recommended Biomarker Testing in NSCLC.
Preparing for Checkpoint Inhibitors in Breast Cancer
EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases  Tao.
Clinical courses of patients.
Multidisciplinary Management in Non-Small Cell Lung Cancer (NSCLC)
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC
(A) Survival time. (A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups.
Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.
Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy.
Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non- small Cell Lung Cancer Patients Aged 70 Years or Older  Yuh-Min Chen,
Third-Generation EGFR TKIs
Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies  Mary Linton B Peters, MD,
Going Beyond EXTREME in Head and Neck Cancer
Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone?  Alvaro Leone, BSc.D 
Physiologic vs Chronologic Age
What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer
Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) for EGFR mutant lung adenocarcinoma.
What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?
Current Status of Biomarkers for Immune Checkpoint Inhibitors
Combining Immunotherapy and Chemotherapy in NSCLC
Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for.
Figure S1. A. B. Figure S1. Kaplan-Meier curve of progression-free survival by treatment group in soluble heregulin (HRG)-high population (A) and soluble.
Physiologic vs Chronologic Age
Updates in Best Practices in Non-Small Cell Lung Cancer
Patterns of clinical relapse and algorithm for the therapeutic strategy when AR to EGFR TKI occurs in patients with EGFR-mutant NSCLC. *After discussion.
Presentation transcript:

EGFR Inhibitors in Advanced NSCLC: Who, When, and Why?

EGFR Mutations and Testing of Lung Cancer Tumors

First-Line Use of EGFR TKIs

EURTAC: Interim Analysis of OS in Intent-to-Treat Population

First-Line Use of EGFR TKIs

EGFR TKI Maintenance Regimens Used in Switch Trials

TORCH Trial Design

BR.21: Erlotinib Beyond the First-Line

EGFR TKIs vs Chemotherapy in Previously Treated Unselected Patients

TAILOR Study Design

SATURN Study Design

SATURN: PFS Stratified by Biomarker Status

ATLAS Study Design

ATLAS: PFS

OS Data for MetMAb and Erlotinib in Key Subpopulations

Resistance to EGFR TKIs

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.